Loading tape…Loading tape…
ILMN
ILMN
ILMN
Illumina Inc has recently reached a new 52-week high, according to defenseworld.net. Against this backdrop, the company reports a full-year revenue of 4,338,000,000 and a market capitalization of approximately 33,016,686,000. It also shows a trailing twelve-month EPS of 5.4635761589403975, paired with a PE ratio of 40.336414048059154 and a free cash flow yield of 2.8440165072896777%.
Based on defenseworld.netWill Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina, Inc. $ILMN Stake Reduced by Krilogy Financial LLC
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Illumina releases SpliceAI2 to help advance rare disease research
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.